Loading...

RVMD REVOLUTION MEDICINES INC Other Situations 8-K Filing

RVLT

RVMD

REVOLUTION MEDICINES INC

(RVMD)

2025 8-K

Financial Results Report

FDA Voucher Granted

Pipeline Update

Financial Statements

Strategic Alliances

Financial Statements

Financial Results

Pipeline Updates

Financial Results

Clinical Trial Update

Pipeline Update

Financial Results and Board...

Pipeline Updates and Financ...

Annual Meeting of Stockholders

Financial Results Announcement

Financial Results Announcement

Amendment to 8-K

Acquisition of EQRx, Inc.

Financial Results Announcement

Merger of Equals

Pipeline Updates

Pipeline Updates

Financial Results Announcement

Merger Agreement

Annual Meeting of Stockholders

Financial Results Announcement

Underwriting Agreement

Financial Results Announcement

Results of Operations and F...

External Links:

On October 16, 2025, Revolution Medicines, Inc. announced that the FDA granted them a non-transferrable voucher for daraxonrasib, their RAS(ON) multi-selective inhibitor, under the National Priority Voucher pilot program.

AI Assistant

REVOLUTION MEDICINES INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.